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Tissue engineering is a pioneering ﬁeld with huge advances in recent times. These advances are not only in the understanding of
how cells can be manipulated but also in potential clinical applications. Thus, tissue engineering, when applied to skeletal muscle
cells, is an area of huge prospective beneﬁt to patients with muscle disease/damage. This could include damage to muscle from
trauma and include genetic abnormalities, for example, muscular dystrophies. Much of this research thus far has been focused
on satellite cells, however, mesenchymal stem cells have more recently come to the fore. In particular, results of trials and further
research into their use in heart failure, stress incontinence, and muscular dystrophies are eagerly awaited. Although no doubt, stem
cells will have much to oﬀer in the future, the results of further research still limit their use.
1.Introduction
Skeletal muscle is the most abundant tissue of the human
body, it is highly dynamic and has the ability to regenerate.
Loss of skeletal muscle through trauma, tumour ablation, or
prolonged denervation is a common clinical challenge.
Despite the ability of muscle ﬁbres to regenerate, muscle
function is often compromised after injury due to the
formation of dense ﬁbrotic scar tissue. This may be induced
by a rise in TGF-B1 and IGF-1, causing postnatal muscle-
derived stem cells (MDSCs) and other myogenic cells to
diﬀerentiate into myoﬁbroblasts, producing type 1 collagen,
themajorcomponentofﬁbrotictissue[1–5].Althoughsome
studies have looked at the eﬀects of blocking components of
the inﬂammatory cascade, such as agents that block TGF-
B1, these treatment methods have potential deleterious side-
eﬀects [6–8].
Skeletal myopathies present a diﬀerent challenge. Mus-
cular dystrophy is caused by a defective gene encoding
dystrophin, which links the extracellular matrix in muscle to
theintracellularcytoskeleton.Asskeletalmuscleiscomposed
of large multinucleated ﬁbres whose nuclei cannot divide,
cell therapy has to restore gene expression in hundreds of
millions of postmitotic nuclei [9].
Clinical application of skeletal muscle engineering in
human subjects thus far has been limited, with clinical
trials on humans concentrating on cardiac disease, stress
incontinence of the bladder, and muscular dystrophies. This
in part is due to the challenges of transferring ex vivo to in
vivo tissue engineering. It is also due to the complexity of
themicroenvironmentneededtoensurestemcellintegration
and function. This review will focus on the potential of
stem cells for skeletal muscle engineering; their sources,
microenvironment, and clinical applicability.
2. Anatomy
The formation of skeletal muscle begins during the fourth
week of embryonic development as specialised mesodermal
cells, termed myoblasts, begin rapid mitotic division. The
cytoplasmic fusion of myoblasts forms what is known as
myotubes, and by week nine of development these can2 Stem Cells International
be identiﬁed as multinucleate skeletal muscle cells, termed
muscle ﬁbres. By month ﬁve, the muscle ﬁbres are accu-
mulating protein ﬁlaments important in muscle contraction.
As growth of the muscle ﬁbres continues, aggregation into
bundles occurs, and by birth myoblast activity has ceased.
Theelectromicroscopicstructureofamuscleﬁbrereveals
a structured longitudinal arrangement of proteins—named
myoﬁlaments. These are arranged in groups within the
muscle ﬁbre known as myoﬁbrils. The major myoﬁlaments
are actin, and myosin. These form functional sub-units
known as sarcomeres. Muscle contraction on a subcellular
levelisacomplexprocessinthesarcomereinvolvinginﬂuxof
calcium ions into the muscle ﬁbre, and interaction between
myosin, actin and the proteins troponin and tropomyosin.
This results in the myoﬁlaments sliding relative to one
another, generation of ATP, shortening of the sarcomere, and
subsequent contraction of the muscle belly.
Contracting muscle ﬁbres would be ineﬀective if they
worked as isolated units. Each ﬁbre is bound to adjacent
ﬁbres to form bundles. An accumulation of muscle bundles
forms the muscle belly itself. Supporting connective tissue is
present, surrounding, and within the muscle. The endomy-
sium surrounds individual ﬁbres, the perimysium encloses
the fascicles, and the epimysium surrounds the muscle belly
itself.
3.Sources
Stem cells may be totipotent, pluripotent, or multipotent,
depending on tissue type. Totipotent cells form all the cells
and tissues that contribute to the formation of an organism.
Only the embryo itself is totipotent. Pluripotent cells can
form most cells of an organism from all three germ cell
layers. Embryonic stem cells present in the fertilised oocyte,
zygote, and morula [10]. Pluripotent cells have the ability
to expand in vitro almost indeﬁnitely and form tissues
from ectoderm, mesoderm, or endoderm. Concerns about
tumour formation in vivo and ethical concerns regarding
their harvest have thus far restricted their use.
Multipotent cells form a number of cells or tissues that
are usually restricted to a particular germ layer. Multipotent
cells are derived from speciﬁc tissue compartments in the
adult. The two main types of multipotent stem cell are
haemopoietic and mesenchymal type, both usually derived
from adult bone marrow, but occasionally from fat, skin,
periosteum, and muscle, as described below. Mesenchymal
stem cells (MSCs) are multipotent, capable of diﬀerentiating
into several connective tissue types including osteocytes,
chondrocytes, adipocytes, tenocytes, and myoblasts [11].
Mesenchymal stem cells have the advantage of being easily
obtainableinadulttissue,andwiththeappropriatemicroen-
vironment, can diﬀerentiate into various target tissue types.
For skeletal muscle engineering, most research thus far
has focused on the satellite cell. The satellite cell was ﬁrst
describedbyMauroin1961,whoobservedthemasmononu-
clear cells between the basal lamina and plasma membrane
(sarcolemma) of the muscle ﬁbre [12]. In response to injury,
satellite cells are activated, diﬀerentiate into myoblasts,
and proliferate. They either fuse with themselves, damaged
muscle ﬁbres, or remain quiescent as satellite cells at the sar-
colemma. Satellite cells are characterised by expression of the
muscle-speciﬁed paired box (Pax) transcription factor Pax7
[13]. They also consist of a majority of Myf5+ cells which act
as an initiator of myogenic diﬀerentiation, marking the com-
mitment of this cell population to the myogenic lineage [14].
Satellite cell usage has been promising. Studies have
demonstrated their ability to regenerate large parts of mus-
culature in vivo with low tumourgenic potential [15, 16].
Extracellular factors are necessary for the function of the
satellitecell,andexvivostudieshaveshownrapiddediﬀeren-
tiation after a few cell cycles [17]. These cells have potential
for the treatment of muscular dystrophy. Early studies in
mice lacking the gene for dystrophin production, showed
thataninjectionofnormalsatellitecellsintothemusclebelly
resulted in fusion with host ﬁbres and extensive production
ofdystrophin[18].Laterstudieshowevershowedanimmune
response to the satellite cells and poor survival [19]. More
eﬃcient methods of delivery have been researched including
transplanting individual muscle ﬁbres (containing at least
seven satellite cells) or isolating “purer” sources of satellite
cells. Although some of these studies have shown promising
results, the inability of these cells to cross the endothelial cell
wall makes systemic delivery impossible, which impacts on
their use to heal diseased diaphragm and cardiac muscles
[20].
MSCs can be obtained from a variety of diﬀerent sources
which can harbour myogenic potential. The ﬁrst evidence
of this was reported in 1998 in transgenic mice, showing
that transplantable progenitors in bone marrow could be
recruited to injured muscle and take part in repair [22].
Many studies have shown their potential in diﬀerentiating ex
vivo into skeletal muscle under the right conditions [23–25].
Some studies have shown a low incorporation rate of MSCs
intomyoﬁbres[26].MSCscanhoweverimposeanadditional
paracrineeﬀectondiﬀerentiationandtissueregenerationvia
cytokine pathways [27]. MSCs, unlike satellite cells maintain
their stem-cell characteristics when systemically delivered
andpassthroughvascularwallsintotargettissues[28].There
are a number of other tissue sources of stem cells for skeletal
muscle engineering which are summarised in Table 1.M S C s
are recognised using a range of cell surface markers as shown
in Figure 1 [21].
4.Matrices
In vivo, the extracellular matrix of muscle provides ﬁbres
with the architecture to support development and function.
It is a highly organised tissue with high cell density, with the
parallel orientation of muscle ﬁbres generating longitudinal
contraction [29]. During tissue engineering, therefore, a
scaﬀold is needed to mimic this matrix. In vivo studies
have shown that stem cells with extracellular matrix, when
injected into damaged muscle such as gastrocnemius, can
signiﬁcantly improve functional recovery when compared to
matrix alone [30]. There are many diﬀerent permutations to
matrix structure and material. Matrix structure can be two-
dimensional or three-dimensional. Scaﬀold material can be
biodegradable or nonbiodegradable. Biodegradable matricesStem Cells International 3
Table 1: Potential of other cell sources for skeletal muscle engineering.
Cell type Source Potential advantages
Skeletal muscle side
population Skeletal muscle
Can be delivered systemically
May have increased capacity to incorporate into stem
cell of muscle
Muscle-derived stem cells Skeletal muscle Can undergo myogenic and osteogenic diﬀerentiation
Can repopulate haematopoietic lineage
Mesoangioblasts Other mesodermal tissues, for
example, dorsal aorta
Can be delivered systemically
May be able to eﬃciently regenerate normal skeletal
muscle
Pericytes
Basement membrane adjacent to
endothelial cells
Pancreas, adipose tissue, placenta
May improve the physiological performance of skeletal
muscle
Can be easily manipulated in vitro to reduce host’s
immune response
Adipocytes Adipose tissue Proven good diﬀerentiation into myogenic cells in vitro
and in vivo
Embryonic stem cells and
induced-pluripotent stem cells
Can regenerate acutely and chronically injured muscle
but concerns of tumourigenic potential and ethical
concerns
can be synthetic or natural. There are relative advantages and
disadvantages to each.
The extracellular matrix of muscle in vivo is three-
dimensional. Traditional cell culture has made use of 2D
(two-dimensional) surfaces for ex vivo cell growth and is
valuable in identifying cell structure and diﬀerentiation.
In such environments, cells are forced to adopt unnatural
characteristics, including aberrant ﬂattened morphologies.
2D culture is not suitable for engineering 3D muscle
tissue. Advantages of 3D over 2D culture include enhanced
proliferationanddiﬀerentiationofstemcells.Inaddition,3D
culture is more likely to accurately reﬂect the in vivo tissue
environments from which cultured cells are derived.
Recent research on 2D “cell sheet technology” has shown
promise, however, using temperature-responsive 2D scaf-
folds made out of a polymer, poly (N-isopropylacrylamide).
Cell layers (with their extracellular matrix) can separate
out with increasing temperature, obviating the need for
enzymes [31]. Parallel alignment of ﬁbres can be reached by
techniques such as “electrospinning” and “microgrooving.”
Microgrooving uses abrasives to create microgrooves within
the matrix and has shown promising results in the orientated
cellgrowthofmyoblasts[32].Electrospinningtechniqueuses
electrical current to form ﬁbres as well as proteins of the nat-
ural extracellular matrix and can uniquely mimic the struc-
ture of the natural extracellular matrix [33]. Out of these 2D
cell sheets, 3D matrices can be made, from 2D layering on a
vascularbed.Onedisadvantageofcell-sheettechnologyisthe
inability of myoblasts to proliferate and diﬀerentiate more
than 150 micrometres from a nutrient source [34]. Also, the
electrospinning of nanoﬁbres can often lead to them being
densely packed, which can lead to poor cell inﬁltration [35].
The vast majority of scaﬀolds developed are biodegrad-
able. When these degrade, remodelling to the natural mus-
cular extracellular matrix can occur [36]. 3D scaﬀolds made
from synthetic material such as polylactic-co-glycolic acid
(PGA) ﬁbre mesh sheets can provide rigidity and connection
[37].Thenano-andmicroscalefeaturesofapolymerscaﬀold
cause alignment of myoblasts and cytoskeletal proteins and
promote myotube assembly to mimic the organisation seen
in skeletal muscle. The surface stiﬀness in the polymer can
help in the diﬀerentiation of satellite cells [38]. Parallel
alignmentcanbeinducedbyapplyingastrongmagneticﬁeld
or mechanical strain [39].
Natural biodegradable 3D scaﬀolds also contain aligned
topographical features causing alignment of myoblasts and
proteins. Fibrin can be used, mixed with satellite cells and
a growth medium. The original ﬁbrin matrix is eventually
taken over by the muscle progenitor cells, which produce
their own extracellular proteins. Fibrin has the advantage of
being able to bind growth factors such as IGF-1. In vitro
models have been encouraging, showing that normal skeletal
muscle in structure and function can be produced [40].
Collagen has also been used as a biodegradable 3D scaﬀold
in some studies to good eﬀect[41] .T h etypeo fp r o t e i n su s e d
for the scaﬀold is important. A recent study in mice showed
that stem cell proliferation and diﬀerentiation using laminin
andMatrigelwassuperiortocollagentype1,ﬁbronectin,and
gelatin [42].
In summary, although a pluripotent cell source is desir-
able, the tumour-forming potential in the use of these cells
at present likely represents an unacceptable risk. Therefore,
taking into account the literature discussed, a satellite cell
source in a 3D matrix with a biodegradable scaﬀold appears
to be the current optimum method of skeletal muscle tissue
engineering.
5. ClinicalApplications
Clinical trials on human subjects are limited due to the
diﬃculties encountered with satellite cells, and the myogenic
potential of alternative progenitor cells, delivery methods of
these cells and the search for the “ideal” matrix. Highlighted
below are the main clinical ﬁndings from human trials.4 Stem Cells International
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Figure 1: Cell surface epitope characterisation of passage 2 infrapatellar fat-pad-derived stem cells using a panel of antibodies. Cell surface
stainingusingFITC-conjugatedsecondaryantibody(green)andDAPI(blue)showsthatthecellsstainstronglyforCD13,29,44,90,and105,
and poorly for 3G5, LNGFR, STRO-1, and CD34 and 56. No staining was observed for the IgG control. The staining pattern is conﬁrmed by
ﬂow cytometry and shows the increase in ﬂuorescence (green) compared with the autoﬂuorescence (black) [21].
5.1. Muscular Dystrophies. These are a group of heterogene-
ous disorders producing progressive weakness, muscle wast-
ing, and in the case of Duchenne muscular dystrophy usually
paralysis and death in the patient’s early 20s. Traditional
treatment was limited to pharmacological suppression of the
immune response with cortocosteroids.
Since the 1990s, from the ﬁrst clinical trial in humans, it
has been shown that stem cell transplantation via intramus-
cular injection can lead to dystrophin production. In 1991,
Lawinjectedextensordigitorumbrevis(EDB)muscleineach
of three Duchenne muscular dystrophy (DMD) boys with
myoblasts. He demonstrated increases in isometric twitchStem Cells International 5
and voluntary contractions whereas sham-injected EDBs
showedreductions.Allpatientsexpresseddystrophinintheir
muscles following injection [43]. The next landmark study
by Law involved 21 patients, with intramuscular injections
of myoblasts. At 3 months, of the 69 muscle groups tested for
isometric force generation in these subjects, 43% showed a
mean increase of 41.3%. Eighty-one percent of the muscles
tested showed either an increase in strength or did not show
continuous loss of strength [44].
Several other studies began to question the longevity
of muscle function following the intramuscular injections.
Karpati et al. [45] showed that 12 months following multiple
intramuscular bicep injections in 8 patients, only 3 had
improved muscle strength. Tremblay et al. [46] showed in 5
patients that one month after myoblast transplantation into
tibialis anterior (TA), the percentage of dystrophin-positive
ﬁbresrangedfrom0–36%, comparedto 0–4% onthe control
side. The expression of dystrophin in these ﬁbres was gener-
ally low and most likely less than 10% of the normal level.
In the biceps brachii on both sides 6 months after the trans-
plantation, less than 1.5% of dystrophin-positive ﬁbres were
detected. No patients had improved strength at followup.
Mendell et al. injected donor myoblasts once a month
for six months into the biceps brachii muscle of one arm
in 12 boys with Duchenne’s muscular dystrophy. Six months
after treatment, there was no signiﬁcant diﬀerence in muscle
strength between the arms injected with myoblasts and
sham-injected arms. In one patient, 10.3 percent of muscle
ﬁbers expressed donor-derived dystrophin after myoblast
transfer. Three other patients also had a low level of donor
dystrophin (<1 percent); eight had none [47].
Neumeyeretal.evaluatedmyoblastimplantationtherapy
in three subjects with Becker muscular dystrophy. Each
patient received 60 million myoblasts implantated into one
TA muscle. They had begun cyclosporine immunosuppres-
sion two months prior to implantation and this was contin-
ued for 1 year. Results showed that myoblast implantation
did not improve strength of the implanted TA muscles [48].
Skuk et al. showed similarly disappointing results after my-
oblast transplantation in the TA of 9 patients with the per-
centage of myoﬁbers expressing donor’s dystrophin varying
from only 3.5% to 26% at 4-week follow-up [49].
Severalotherstudieshaveshownasimilartrend,butwith
no signiﬁcant improvement in muscle function [50]. One
of the problems with intramuscular injections for systemic
conditionsistheneedtoperformlargenumbersofinjections
to target diﬀerent areas of muscle in order to gain a clinical
response. Secondly, as already highlighted, vital muscles,
such as the diaphragm for respiration, are not suitable for
this form of treatment.
It was shown by Gussoni et al. [51] in mice that a
marrow-derived cell could migrate into areas of muscle de-
generation, undergo myogenic diﬀerentiation, thereby
participating in muscle repair. Systemic delivery obviously
holds the advantage of negating the need for multiple
injections into the muscle belly, although an immune
response to these cells is possible. Recent developments in
the ﬁeld of gene transfer therapy promise hope for future
treatment possibilities. Cassano et al. recently showed
that electrotransfer of “Magic”-Factor-1 gene into adult
mice promoted muscular hypertrophy, improved running
performance, and accelerated muscle regeneration after
injury [52]. Phase I trials after gene transfer in patients with
Duchennemusculardystrophyhaveshownnoadverseevents
[53].
It is likely that a strategy for treatment of these disorders
will require a combination of stem cell and gene transfer
techniques and we await the results in a few years time from
ongoing trials.
5.2. Heart Failure. Like skeletal muscle cells, myocardial cells
are striated; containing actin and myosin ﬁlaments arranged
in the form of sarcomeres. They diﬀer in that they intercon-
nect through gap junctions to transfer electrical impulses.
Muscle-derived myoblasts are considered an optimal cell
therapy for heart failure, as they can be easily obtained from
thesamepatient,rapidlyexpandedinvitro,andtransplanted
back into the patient’s heart [20].
Several randomised controlled trials have shown beneﬁts
after transepicardiol injections of skeletal myoblasts [54–56].
Patients have beneﬁted through an increased left ventricu-
lar ejection fraction, end-systolic volume, and subsequent
symptomatic improvement. Concern remains about the
increased occurrence of ventricular tachycardia following
treatment. Ex vivo studies have shown embryonic stem cells
to be of value in the development of new myocardial tissue
[57].
5.3. Stress Urinary Incontinence. Stress urinary incontinence
(SUI) is characterised by the loss of small amounts of urine
when intra-abdominal pressure increases through laughing,
coughing, or exercising. Muscle, connective tissue, and nerve
damage during childbirth appears to be the most important
risk factor [58]. Traditional treatment options of pelvic ﬂoor
muscle training, pharmacological agents, and surgical solu-
tions have had limited success. Recently, stem cell treatment
has focused on treating the connective tissue and skeletal
muscle component of the rhabdosphincter—thought to be
the structure most important in controlling continence [59].
Most clinical trials in humans have involved muscle-
derived stem cells injected under transurethral ultrasound
guidance, together with a ﬁbroblast/collagen suspension
followed by pelvic ﬂoor exercises and transvaginal electrical
stimulation [60, 61]. Numerous studies have shown beneﬁt
in females with stress incontinence, showing one-year cure
rates up to 93% [60–63]. These patients have shown
increased electromyelogram activity in the rhabdosphincter
and increased urethral thickness. There have been reported
beneﬁts of using autologous-derived adipose stem cells in
some patients [64]. Studies have also shown beneﬁts of using
stem cells in men for postprostatectomy stress incontinence
[65].
6. Summary
Stem cells are emerging as a potential source of tissue repair
and regeneration in many musculoskeletal tissues [66–80].6 Stem Cells International
Although most advances have been made with bone, carti-
lage, tendon, and ligaments [81–109], this review shows that
the application of stem cells in skeletal muscle regeneration
following injury and disease is slowly emerging. Although
satellite cells have attracted much interest due to their
commitment to the myogenic lineage, their ability to cross
the endothelial junction is limited, thus meaning locallyde-
livered transplantations are required. An appropriate matrix
is needed to cultivatestemcellsprior to their delivery in vivo.
Human trials thus far have concentrated mainly on patients
with muscular dystrophies, heart failure, and stress urinary
incontinence. While successful results have been shown
in patients treated with myoblast transplantation in heart
failure and urinary incontinence, stem cell use in muscular
dystrophies has so far been limited. Recent studies using
gene therapy in combination with stem cell transplantation
has shown some promise. Treatment using stem cells for
skeletal muscle regeneration should combine a systemically
delivered progenitor cell with controlled diﬀerentiation into
myoblasts in vivo which can cross the endothelial lining
of the blood vessel and target damaged muscle. We look
forward to future studies developing current techniques and
highlighting potential uses in the regeneration of skeletal
muscle following trauma and disease.
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